stockrowIDEXX Laboratories, Inc.
IDXX Healthcare Diagnostics & Research
IDEXX Laboratories, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, up 10.4% from fiscal 2024.
- Revenue
- +9.86%
- EPS
- +17.3%
- Free cash flow
- +17.6%
- Total debt
- −28.6%
Quarter to September 2026, against a year earlier
Follow IDXX
Alert me
IDEXX Laboratories, Inc. (IDXX) Return on equity
IDEXX Laboratories, Inc.'s return on equity over the twelve months to 30 September 2026 was 68.9%, up 2.7 percentage points from fiscal 2025 (66.2%). Over the past ten years it has ranged from −1,195.5% (fiscal 2018) to 1,143.5% (fiscal 2015); the current reading is higher than 45% of that period. That is above the Diagnostics & Research industry median of 0.00% and above the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | 66.2% | 8.54 |
| FY2024 | 57.7% | (23.08) |
| FY2023 | 80.7% | (23.84) |
| FY2022 | 104.6% | (8.04) |
| FY2021 | 112.6% | (30.92) |
| FY2020 | 143.5% | (363.86) |
| FY2019 | 507.4% | 1,702.90 |
| FY2018 | −1,195.5% | (870.74) |
| FY2017 | −324.8% | (93.71) |
| FY2016 | −231.1% | (1,374.58) |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| IDXX IDEXX Laboratories, Inc. | 68.9% |
| ILMN Illumina, Inc. compare | 32.4% |
| IQV IQVIA Holdings Inc. compare | 21.3% |
| A Agilent Technologies, Inc. compare | 21.0% |
| DGX Quest Diagnostics Incorporated compare | 14.8% |
| LH Labcorp Holdings Inc. compare | 11.5% |
| WAT Waters Corporation compare | 0.00% |
| NTRA Natera, Inc. compare | −10.6% |
| MTD Mettler-Toledo International, Inc. compare | −736.4% |
| Diagnostics & Research industry median | 0.00% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on IDXX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement